# Gregory Ho

> Gregory Ho is a Series A investor at Spring Mountain Capital backing Health Care and Therapeutics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Spring Mountain Capital](https://shizune.co/investors/profile/spring-mountain-capital)
- Location: New York, United States
- Total investments: 6
- Last investment: Jan 2020
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gregory-ho-68126215/

Gregory Ho is a Series A investor at Spring Mountain Capital in New York focused on Health Care and Therapeutics. Gregory Ho has served as the President and Chief Operating Officer of SMC since its founding in June 2001. Previously, he was a Principal and Chief Financial Officer of McKinsey & Company, Inc. During his 16 years with McKinsey, he led the financial and tax planning for the firm and its worldwide partner group, as well as the identification,evaluation, and selection of traditional and alternative asset managers for over $1 billion of assets in its qualified employee plans and in-house investment office. Gregory Ho was also a Trustee of McKinsey's Profit-Sharing Retirement Plan and a member of the firm's Investment Committee. After leaving McKinsey in 1998 and prior to joining SMC, Gregory Ho was a private investor and consultant. Prior to joining McKinsey, he was associated with the law firm of Donovan Leisure Newton & Irvine. Gregory Ho received a J.D. from Columbia Law School and a B.S., with honors, in Administrative Science from Yale College. He is a member of the New York Bar and the California Bar.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Therapeutics | 2 | 33% |
| Biotechnology | 2 | 33% |
| Catering | 1 | 17% |
| Hospitality | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Seed | 1 | 17% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| IsoPlexis | IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. |  | Series C | Jan 09, 2020 |  |
| IsoPlexis | IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. |  | Series C | May 14, 2019 |  |
| Junzi Kitchen | Founded in 2015, junzi grew out of a hunger for our childhood staples: northern Chinese food made with healthy, seasonal ingredients. Yet recreating the taste of home has done much more than sate our cravings—the amazing power of food in building community has inspired us to make our bings and noodles accessible to all. In just three years,we’ve grown junzi to four locations in New Haven, CT near Yale University, Morningside Heights near Columbia University, Greenwich Village near NYU and (soon-to-open) Bryant Park—and that’s just the beginning! | $1.8M | Seed | Aug 01, 2018 |  |
| ReNetX Bio | ReNetX Bio first-in-class therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI)and glaucoma. |  | Series A | May 07, 2018 |  |
| IsoPlexis | IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. | $13.5M | Series B | Sep 25, 2017 |  |
| IsoPlexis | IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. | $1.3M | Series A | Aug 12, 2014 |  |

6 of 6 investments shown.

## Co-investors
- [Connecticut Innovations](https://shizune.co/investors/profile/connecticut-innovations) — VC Fund, 3 deals together
- [Ironwood Capital](https://shizune.co/investors/profile/ironwood-capital) — VC Fund, 3 deals together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 2 deals together
- [Advantage Capital](https://shizune.co/investors/profile/advantage-capital-partners) — VC Fund, 1 deal together
- [North Sound Capital](https://shizune.co/investors/profile/north-sound-capital) — VC Fund, 1 deal together
- [North Sound Ventures](https://shizune.co/investors/profile/north-sound-ventures) — VC Fund, 1 deal together

## About Spring Mountain Capital

VC Fund · New York, United States

Spring Mountain Capital focuses on providing expansion capital to companies capitalizing on breakthrough innovations, paradigm shifts, or fundamental market or behavioral changes. SMC invests in sectors of the U.S. economy undergoing the most change and with the highest growth potential: enterprise software, technology-enabled services, digitalhealth, and healthcare services.

5 contacts available at Spring Mountain Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Gregory Ho | President and Chief Operating Officer | https://shizune.co/investors/profile/gregory-p-ho |
| Jamie Weston | Managing Director | https://shizune.co/investors/profile/jamie-weston |
| John Gu | Principal | https://shizune.co/investors/profile/john-gu |
| John Steffens | Founder & Senior Managing Director | https://shizune.co/investors/profile/launny-steffens |
| Kenneth Soll | Vice President | https://shizune.co/investors/profile/kenneth-soll |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gregory Ho invest in?

Gregory Ho invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gregory Ho last invest?

The most recent investment recorded for Gregory Ho closed in Jan 2020. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co